Over 80% of Americans want to spend their last days at home, with friends and family. Yet, despite these desires, 75% of Americans will spend their last days in a hospital room. Many people will spend hours each day getting painful and often useless treatments and tests, and be asked to take dozens of debilitating drugs. For many, the cure is worse than the disease. This often has negative and lasting effects on family and friends who are often left with feelings of guilt and regret for years to come.
Hospice Support Fund is a 501(c)(3) non-profit organization dedicated to promoting end of life care at home rather than in a hospital so patients can spend their last days in dignity and peace, pain-free in familiar, comfortable surroundings with friends and family.
To view the multimedia release go to:
http://www.multivu.com/players/English/7785451-hospice-support-fund-end-of-life-care-psa/
According to a recent national survey, 17.1 percent of Americans lack health insurance, and more than nine million of the nation’s uninsured rely on federally qualified health centers (FQHC), non-profit community clinics and free clinics each year for primary care. While these clinics serve the critical health care needs of the uninsured, patients oftentimes cannot afford the medications prescribed by the clinic’s physicians, or navigate a fragmented system that only offers partial solutions. This is a particularly growing problem for America’s working poor.
Today, Medco Foundation and Dispensary of Hope (DOH), a not-for-profit pharmacy-focused social venture for the uninsured, introduced a new, national initiative to substantially improve the supply, delivery and management of critical prescription drugs to thousands of uninsured Americans who are managing a chronic illness.
To view Multimedia News Release, go to http://www.multivu.com/mnr/54424-medco-dispensary-of-hope-prescription-drug-program-clinics-uninsured
Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, Epilog.us [http://www.Epilog.us], now features a panel discussion of leading experts on the role of rational polytherapy in the treatment of patients with epilepsy, led by Dr. Barry Gidal, Professor of Pharmacy and Neurology/Division Chair, University of Wisconsin. Dr. Gidal also brings forward discussion on the mechanism of action of specific antiepileptic drugs (AEDs). Additional topics include: AED pharmacokinetics; patient adherence and AEDs; and drug interactions.
To view Multimedia News Release, go to http://www.multivu.com/mnr/59891-upsher-smith-epilog-us-pharmacodynamics-of-antiepileptic-drugs-aeds
The American Pain Foundation (APF) announced today the launch of new information and resources on pain medication safety for acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) as a part of its PainSAFE™ educational initiative. The new information will be launched with a national public service announcement (PSA) emphasizing the safe use of pain treatment options, particularly medications containing NSAIDs (aspirin, ibuprofen, naproxen) and acetaminophen (Tylenol, APAP). APF is the nation’s largest consumer advocacy organization dedicated to people with pain.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/painfoundation/49865/
OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
Each day in the U.S. 91 people die from an opioid-related overdose, and the numbers are increasing. In observance of International Overdose Awareness Day on August 31, American Addiction Centers (AAC) and Recovery Brands are launching a nationwide awareness campaign on how to prevent deaths from opioid overdoses. The campaign features shareable online resources, including an animation video about how an overdose impacts a body, an infographic about how to administer overdose medication, and powerful videos of survivors sharing the life-saving lessons they learned during their darkest hours.
“This is a meaningful endeavor as we partner with our parent company, AAC, in order to present several life-saving resources for people impacted by addiction,” said Ruchi Dhami, director of market insights and development at Recovery Brands, a provider of digital addiction treatment resources. “Since such a large amount of individuals look for information online about addiction and treatment, we wanted to ensure comprehensive education surrounding opioid overdoses existed and is easily accessible for individuals and families impacted by addiction.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8130951-american-addiction-centers-opioid-overdose/
Iroko Pharmaceuticals, LLC, a Philadelphia-based pharmaceutical company focused on the development and commercialization of innovative therapeutic products, today announced the opening of its new environmentally friendly corporate headquarters in Philadelphia’s Navy Yard Corporate Center. This milestone is part of the Company’s long-term growth plan as it advances its late-stage pipeline of lower dose submicron non-steroidal anti-inflammatory drugs (NSAIDs) towards commercialization.
To view Multimedia News Release, go to http://www.multivu.com/mnr/58559-iroko-pharmaceuticals-opens-philadelphia-headquarters-hq
A recent survey conducted by Harris Poll on behalf of the newly-formed Coalition to Prevent Attention-Deficit/Hyperactivity Disorder (ADHD) Medication Misuse (CPAMM) finds that college students’ perceptions and attitudes towards the misuse, abuse and diversion of ADHD prescription stimulants are complex. The findings paint a portrait of students who recognize the risks of misuse, but understand why some students may choose to misuse, given the academic pressures in today’s college environment. CPAMM intends to use the findings to inform and develop educational campaigns to help prevent nonmedical use of ADHD prescription stimulants. The survey was conducted online between May 15 and June 11, 2014 among 2,056 US college students (full-time, 91%, part-time, 9%), defined as adults aged 18 to 24 enrolled and seeking a degree at a 4-year college or university and attending at least some in-person classes.1
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7373051-cpamm-survey-reveals-college-students-adhd-prescription-stimulant-abuse-misuse-and-diversion/
Globally, 1.2 billion people have no access to electricity. On the occasion of VELUX 75th anniversary the company decided to address this issue. Together with the social business Little Sun and the NGO Plan International they are collaborating to bring clean, reliable and affordable light to off-grid regions in Zambia, Sierra Leone and Zimbabwe.
14,500 Natural Light lamps from the VELUX Group have now arrived in Africa and the first recipients can already look forward to a better quality of life.
Among them are young girls between 10 and 18 years of age who live in a safe house in the slum area Mntendere in the Zambian capital Lusaka.
"The lamps mean the girls can do their homework when they get back from school and can feel safer at night, instead of huddling together in the dark after sunset. And it’s particularly important for our children that they feel safe – many are carrying the mental baggage such as the trauma of violence, rape or drugs," says safe house manager Verann Delarey.
To view the multimedia release go to:
http://www.multivu.com/players/uk/7769151-velux-natural-light-and-life-zambia/
